| General Information |
| Business: |
(Incorporated in Delaware)
We are a Phase 2 biopharmaceutical company developing continuous delivery technology for existing FDA-approved cancer treatments. Our lead program, STAR-LLD, targets multiple myeloma and chronic lymphocytic leukemia. We are investigating the potential of combining STAR-LLD with CAR-T therapies and extending our work to include other types of cancer such as B-cell lymphomas and solid tumors.
|
| Industry: |
Pharmaceuticals |
| Employees: |
7 |
| Founded: |
2017 |
| Contact Information |
| Address |
215 College Road, Suite 300, Paramus, NJ 07652 |
| Phone Number |
(800) 449-5405 |
| Web Address |
http://www.startontx.com/ |
| View Prospectus: |
Starton Holdings |
| Financial Information |
| Market Cap |
$262.0mil |
| Revenues |
$0.0 mil (last 12 months) |
| Net Income |
$-14.44 mil (last 12 months) |
| IPO Profile |
| Symbol |
STA |
| Exchange |
NASDAQ |
| Shares (millions): |
6.7 |
| Price range |
$5.00 - $7.00 |
| Est. $ Volume |
$40.0 mil |
| Manager / Joint Managers |
Revere Securities |
| CO-Managers |
|
| Expected To Trade: |
|
|
Status:
|
TBA |
| Quiet Period Expiration Date: |
Available only to Subscribers |
| Lock-Up Period Expiration Date: |
Available only to Subscribers |
| SCOOP Rating |
Available only to Subscribers |
| Rating Change |
Available only to Subscribers |
